Recently, Liu and colleagues discovered that IRAK1 inhibitors can overcome radiation resistance in TP53-mutated cell lines, that is, head and neck squamous cell carcinoma, breast cancer, and colorectal cancer. This evidence concerns the gene IRAK1 and colorectal cancer.